PF-01367338

Known as: PARP1 Inhibitor PF-01367338 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
02420112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2013
2013
poly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
Is this relevant?
2013
2013
Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2011
2011
e13576 Background: PARP is a key enzyme involved in base-excision repair. Pre-clinically it has been shown that BRCA1/2 deficient… (More)
Is this relevant?
2011
2011
e13552 Background: Within the past several years multiple PARP inhibitors have been entered into clinical trials, in a variety of… (More)
Is this relevant?
2011
2011
e13615 Background: PF-01367338 is a poly (ADP-ribose) polymerase (PARP) inhibitor. The phosphate salt of PF-01367338 (PF-01367338… (More)
Is this relevant?
2011
2011
3104 Background: AG-014699 (PF-01367338) is an intravenous, potent, selective PARP-1 and 2 inhibitor (Ki = 1.4 nM). In pre… (More)
Is this relevant?
2011
2011
3054 Background: PARP activity in PBLs or PBMs, measured as poly(ADP-ribose) (PAR) levels, has been used as a biomarker in the… (More)
Is this relevant?